000217821 001__ 217821
000217821 005__ 20180317093223.0
000217821 0247_ $$2doi$$a10.1080/15384101.2015.1121332
000217821 022__ $$a1538-4101
000217821 02470 $$2ISI$$a000369854900013
000217821 037__ $$aARTICLE
000217821 245__ $$aNon-integrating episomal plasmid-based reprogramming of human amniotic fluid stem cells into induced pluripotent stem cells in chemically defined conditions
000217821 260__ $$aPhiladelphia$$bTaylor & Francis Inc$$c2016
000217821 269__ $$a2016
000217821 300__ $$a16
000217821 336__ $$aJournal Articles
000217821 520__ $$aAmniotic fluid stem cells (AFSC) represent an attractive potential cell source for fetal and pediatric cell-based therapies. However, upgrading them to pluripotency confers refractoriness toward senescence, higher proliferation rate and unlimited differentiation potential. AFSC were observed to rapidly and efficiently reacquire pluripotency which together with their easy recovery makes them an attractive cell source for reprogramming. The reprogramming process as well as the resulting iPSC epigenome could potentially benefit from the unspecialized nature of AFSC. iPSC derived from AFSC also have potential in disease modeling, such as Down syndrome or -thalassemia. Previous experiments involving AFSC reprogramming have largely relied on integrative vector transgene delivery and undefined serum-containing, feeder-dependent culture. Here, we describe non-integrative oriP/EBNA-1 episomal plasmid-based reprogramming of AFSC into iPSC and culture in fully chemically defined xeno-free conditions represented by vitronectin coating and E8 medium, a system that we found uniquely suited for this purpose. The derived AF-iPSC lines uniformly expressed a set of pluripotency markers Oct3/4, Nanog, Sox2, SSEA-1, SSEA-4, TRA-1-60, TRA-1-81 in a pattern typical for human primed PSC. Additionally, the cells formed teratomas, and were deemed pluripotent by PluriTest, a global expression microarray-based in-silico pluripotency assay. However, we found that the PluriTest scores were borderline, indicating a unique pluripotent signature in the defined condition. In the light of potential future clinical translation of iPSC technology, non-integrating reprogramming and chemically defined culture are more acceptable.
000217821 6531_ $$aamniotic fluid stem cells
000217821 6531_ $$aepisomal reprogramming
000217821 6531_ $$aE8
000217821 6531_ $$ainduced pluripotent stem cells
000217821 6531_ $$aPluriTest
000217821 6531_ $$avitronectin
000217821 6531_ $$axeno-free culture
000217821 700__ $$aSlamecka, Jaroslav$$uUniv Zurich, Swiss Ctr Regenerat Med, Zurich, Switzerland
000217821 700__ $$aSalimova, Lilia$$uUniv Zurich, Swiss Ctr Regenerat Med, Zurich, Switzerland
000217821 700__ $$aMcclellan, Steven
000217821 700__ $$aVan Kelle, Mathieu
000217821 700__ $$aKehl, Debora$$uUniv Zurich, Swiss Ctr Regenerat Med, Zurich, Switzerland
000217821 700__ $$aLaurini, Javier$$uUniv S Alabama, Coll Med, Mobile, AL USA
000217821 700__ $$aCinelli, Paolo$$uUniv Zurich, Inst Lab Anim Sci, Zurich, Switzerland
000217821 700__ $$aOwen, Laurie$$uUniv S Alabama, Mitchell Canc Inst, Mobile, AL 36688 USA
000217821 700__ $$aHoerstrup, Simon P.$$uUniv Zurich, Swiss Ctr Regenerat Med, Zurich, Switzerland
000217821 700__ $$aWeber, Benedikt$$uUniv Zurich, Swiss Ctr Regenerat Med, Zurich, Switzerland
000217821 773__ $$j15$$k2$$q234-249$$tCell Cycle
000217821 909CO $$ooai:infoscience.tind.io:217821$$particle$$pSV
000217821 909C0 $$0252372$$pSV$$xU10445
000217821 937__ $$aEPFL-ARTICLE-217821
000217821 973__ $$aEPFL$$rREVIEWED$$sPUBLISHED
000217821 980__ $$aARTICLE